US equities
|
MU
$1,097.39
▲+0.00%
NVDA
$230.86
▲+0.00%
SNDK
$1,787.69
▲+0.00%
MSTR
$160.50
▲+0.00%
NKE
$35.15
▲+0.00%
INTC
$120.00
▲+0.00%
AMD
$615.73
▲+0.00%
AVGO
$343.64
▲+0.00%
MU
$1,097.39
▲+0.00%
NVDA
$230.86
▲+0.00%
SNDK
$1,787.69
▲+0.00%
MSTR
$160.50
▲+0.00%
NKE
$35.15
▲+0.00%
INTC
$120.00
▲+0.00%
AMD
$615.73
▲+0.00%
AVGO
$343.64
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
571.38
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
Next >
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
September 30, 2026
From
United Therapeutics
Via
Business Wire
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
September 08, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
September 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
September 01, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
August 28, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
August 24, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
August 17, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
August 05, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
July 29, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
July 23, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
July 22, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Acquires Thymmune Therapeutics
July 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
June 29, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
May 27, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
May 18, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
May 17, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
May 15, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
May 12, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
May 11, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
May 06, 2026
From
United Therapeutics Corporation
Via
Business Wire
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
May 06, 2026
From
MannKind
Via
GlobeNewswire
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
April 29, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
April 22, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
April 20, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
April 08, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
March 30, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
March 11, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
March 09, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
March 03, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
March 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
< Previous
1
2
3
4
5
Next >
